细针穿刺活检细胞块能否作为乳腺癌组织样本的替代物?
该研究旨在验证细针穿刺活检(FNAB)来源细胞块中检测的生物学标志物能否反映手术样本的特征。研究对93例乳腺癌患者的FNAB细胞块进行免疫组化和荧光原位杂交,检测ER、PgR、Ki67和HER2,并与手术样本的组织学评估结果比较。结果显示细胞块与手术样本的ER、PgR、Ki67中位免疫阳性值相似,ER和PgR一致率分别为98%和84%,Ki67和HER2一致率分别为90%和96%,三阴性和HER2阳性亚型分类完全一致。结论认为FNAB细胞块中检测生物标志物可行,可作为组织样本的替代用于早期乳腺癌标志物评估。
要点
- FNAB细胞块与手术样本的ER、PgR、Ki67中位免疫阳性值相似。
- ER和PgR一致率分别为98%和84%,Ki67和HER2一致率分别为90%和96%。
- 三阴性和HER2阳性亚型分类在细胞块与手术材料间完全一致。
核心结论
- FNAB来源细胞块中检测生物标志物可行,结果与组织学评估相当。
- 细胞块可作为组织样本的替代用于早期乳腺癌生物标志物评估,因其成本低且对患者影响小。
研究设计与样本
- 对93例乳腺癌患者的FNAB来源细胞块进行免疫组化和荧光原位杂交,检测ER、PgR、Ki67和HER2。
- 将细胞块结果与同一患者手术样本的组织学评估结果进行比较。
主要发现
- 细胞块与手术样本中ER、PgR和Ki67的中位免疫阳性值相似。
- ER和PgR的一致率分别为98%和84%。
- Ki67和HER2的一致率分别为90%和96%。
- 三阴性和HER2阳性乳腺癌的亚型分类在细胞块与手术材料间始终一致。
关键数值与推荐
- ER一致率98%,PgR一致率84%,Ki67一致率90%,HER2一致率96%(FNAB细胞块 vs 手术样本)。
- 三阴性和HER2阳性亚型分类完全一致。
临床怎么用
- 可考虑使用FNAB来源细胞块进行早期乳腺癌生物标志物评估,以替代组织样本。
- 细胞块检测成本低且对患者影响小,适合微创诊断场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The diagnosis of breast cancer (BC) is based on clinical examination in combination with imaging, and confirmed by pathological assessment of core needle biopsy or fine-needle aspiration biopsy (FNAB). The biological profile of the lesion is needed to define the prognosis and establish therapy. Given the importance of an early and minimally invasive diagnosis, we aimed to verify whether the biological features detected in FNAB-derived cytological material reflect the biological characteristics of surgical samples. METHODS AND RESULTS: We used immunohistochemistry and fluorescence in-situ hybridisation to study a panel of conventional biomarkers [oestrogen receptor (ER), progesterone receptor (PgR), Ki67, and human epidermal growth factor receptor 2 (HER2)] in FNAB-derived cytological samples included in cell blocks of 93 BC patients, and compared the results with those obtained from histological evaluation of the same parameters in surgical samples. Median immunopositive values of ER, PgR and Ki67 were similar in cell blocks and surgical samples. The concordance rates of ER and PgR between FNAB-derived cell blocks and histological samples were 98% and 84%, respectively. The concordance rates of Ki67 and HER2 between the two sample types were 90% and 96%, respectively. Tumour subtype classification for triple-negative and HER2-positive BCs in FNAB-derived cell blocks was always concordant with the subtype determined in surgical material. CONCLUSIONS: We demonstrated that biological marker determination in FNAB-derived cell blocks is feasible, and provides useful information and comparable results to those obtained with histological evaluation. Given the low cost of the procedure and its minimal impact on patients, we believe that cytological samples could be used as an alternative to tissue samples for early BC biomarker evaluation.
引用
- Puccetti M, Ravaioli S, Tumedei MM, et al. Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? Histopathology. 2018. PMID: 29944734. doi:10.1111/his.13694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。